

Supplementary Materials for
**Transcription factors form a ternary complex with NIPBL/MAU2 to
localize cohesin at enhancers**

Gregory Fettweis[†], Kaustubh Wagh[†], Diana A. Stavrevat, Alba Jiménez-Panizot,
Sohyoung Kim, Michelle Lion, Andrea Alegre-Martí, Lorenzo Rinaldi, Thomas A.
Johnson, Manan Krishnamurthy, Li Wang, David A. Ball, Tatiana S. Karpova, Arpita
Upadhyaya, Didier Vertommen, Juan Fernández Recio, Eva Estébanez-Perpiñá, Franck
Dequiedt*, and Gordon L. Hager*

[†] Co-first authors

* Corresponding authors: F.D. (fdequiedt@uliege.be), G.L.H.
(hagerg@exchange.nih.gov)

This PDF includes

Figures S1 to S4

Tables S1 and S2

Videos S1 and S2

Figure S1




Figure S1: The role of Leu-rich clusters in NIPBL dynamics and biology

- (A) Schematic describing the generation of the IPTG-inducible NIPBL-KD cell line, and subsequent ectopic expression of mNIPBL-WT, C1^{mut}, C2^{mut}, C1+C2^{mut}, or empty vector (EV, 3xFLAG-Halo alone). The middle panel shows the reduction in *Nipbl* mRNA upon 72 h of 1 mM IPTG treatment.
- (B) RNA-seq reads of the ectopic mNIPBL constructs normalized to the highest expression. Error bars represent the standard deviation.
- (C–F) (Left) Ensemble mean-squared displacement (MSD) curves for the indicated species. State 1 is depicted in red, state 2 in blue, state 3 in green, and state 4 in yellow. The numbers above the MSD curves indicate the population fraction of the respective states. Error bars denote the standard error. (Right) Swarmcharts of the maximum posterior probability for each state detected by pEMv2. Colors match those of the states presented in the MSD plots. States with less than 5% population fraction are presented in black. Inset of panel F (left) shows the same MSD curve as panel F with higher y-axis limits.
- (G) Transition probability bar plots for transitions from the states indicated on the x-axes to state 1 (red), state 2 (blue), or any ‘other’ state (grey). The cyan swarmcharts show the transition probabilities calculated from 1000 randomized ensembles of trajectories and the numbers above the bars denote the fraction of randomized ensembles that have a transition probability higher than the respective calculated transition probability.
- (H) Volcano plots of the $-\log_{10}\text{FDR}$ and $\log_2(\text{fold change})$ showing the differential expression of genes under basal conditions (cells grown in charcoal-stripped FBS containing medium). (Top) cl15-EV (+ IPTG) vs cl15-EV (without IPTG). (Bottom) cl15-WT (+ IPTG) vs cl15-EV (without IPTG). The black circles denote genes that do not meet either the FDR or fold-change cut-offs, green circles denote those that only meet the fold-change cut-off, blue circles denote those that only meet the FDR cut-off, and the red circles denote the genes that meet

both the fold-change and FDR cut-offs. Dashed lines indicate the FDR and fold-change thresholds. (Insets) the number of up and down-regulated genes in each condition.


Related to Figure 1.

Figure S2

A

NIPBL interacts with cohesin subunits


Interaction-induced luciferase activity



B


'Barrel-like' conformation

mMAU2-mNIPBL¹⁻¹²⁰ complex
AlphaFold2-Multimer prediction



Mus musculus


Scc4-Scc2¹⁻¹⁸¹ complex
PDB code: 4XDN



Saccharomyces cerevisiae


C

NIPBL interacts with TFs detected in proteomics



D

TFs vs NIPBL full length



E

TFs vs MAU2 full length




Figure S2: Gaussia protein-fragment complementation assay (gPCA) detects direct interactions between proteins

- (A) (Left) Schematic representation of a gPCA experiment. (Right) Normalized luminescence ratio (NLR) for gPCA experiments measuring interactions between hNIPBL-WT and cohesin sub-units and CTCF.
- (B) Comparison of the mouse MAU2-NIPBL complex prediction (left) with the crystal structure of the yeast Scc4-Scc2 complex (PDB: 4XDN) (right). Notice the structural resemblance of the 'barrel-like' conformation of MAU2/Scc4 surrounding the NIPBL/Scc2 region.
- (C–E) NLRs for gPCA experiments between (C) NIPBL-WT and three transcription factors (TFs) detected in the proteomics experiments, (D) NIPBL-WT and the indicated TFs, (E) hMAU2 and the indicated TFs.

Positive interactions are indicated in green while negative interactions are in black. Error bars show the standard deviation across multiple measurements.

Related to Figure 2.


Figure S3

Figure S3: NIPBL-C2 interacts with steroid receptor ligand-binding domains

- (A–B) NLRs of interactions measured by gPCA between nuclear receptors and (A) full-length NIPBL-WT and (B) MAU2. Positive interactions are indicated in green while negative interactions are in black. Error bars represent the standard deviation.
- (C–D) NLRs of gPCA interactions between NIPBL-C2^{WT} and C2^{mut} domains and (C) AR and (D) ER. **p<0.01 (paired t-test).
- (E) Schematic of a surface plasmon resonance (SPR) experiment.
- (F) AlphaFold prediction of the structure of the structured region of human NIPBL containing the C2 LxxLL motif cluster. Residues from the synthesized peptide used for the SPR experiment are depicted in yellow and the exact LxxLL motif sequence used for AlphaFold2-Multimer predictions is colored in ochre.
- (G) Superposition of the 20 best AlphaFold2-Multimer models showing the interaction between the C2^{WT} peptide and (left) human GR, (middle) human AR, and (right) human ER.

Related to Figure 3.

Figure S4




Figure S4: NIPBL mutants alter a subset of glucocorticoid receptor-regulated genes

Heatmap of genes whose Dex-induced fold change is significantly affected (FDR = 0.1) in at least one of the NIPBL-KD and/or NIPBL-WT/C1^{mut}/C2^{mut}/C1+C2^{mut} conditions relative to EV (no IPTG, with endogenous NIPBL), separated by those activated (left) or repressed (right) in response to Dex treatment. The bottom bar plots indicate the average expression of the genes in the indicated clusters.

Related to Figure 4.

Table S1: Sources for the ORFs used for the gPCA experiments

ORF	SOURCE
ARID5A	Human orfeome database v7.1
BCL6	Human orfeome database v7.1
CREB1	Human orfeome database v7.1
E2F1	Human orfeome database v7.1
ESR1	Human orfeome database v7.1
ESR2	Human orfeome database v7.1
FOXM1b	Human orfeome database v7.1
GATA3	Human orfeome database v7.1
HOXA5	Human orfeome database v7.1
HOXA9	Human orfeome database v7.1
HSF1	Human orfeome database v7.1
JUN	Human orfeome database v7.1
LEF1	Human orfeome database v7.1
MYC	Human orfeome database v8.1
MYB	Human orfeome database v7.1
MYOD1	Human orfeome database v7.1
NFKB1	Yvette Habraken Lab
POU2F1	Human orfeome database v7.1
REL	Human orfeome database v7.1
RELA	Human orfeome database v7.1
RUNX1	Human orfeome database v7.1
SMAD4	Human orfeome database v8.1
STAT1	Human orfeome database v7.1
STAT5A	Human orfeome database v7.1
STAT5B	Human orfeome database v7.1
TBX21	Human orfeome database v7.1
THAP11	Human orfeome database v7.1
THRA	Human orfeome database v7.1
TP53	Human orfeome database v7.1
WT1	Human orfeome database v7.1
NIPBL	This study

MAU2	This study
SMC1A	Addgene #32363
SMC3	Addgene #156447
RAD21	Addgene #156445
PDS5B	Addgene #156442
CTCF	Addgene #40801
AR	Gordon Hager Lab
THRΒ	Gordon Hager Lab
GR	Gordon Hager Lab
PPAR α	Gordon Hager Lab
RXR	Gordon Hager Lab
DDIT3	Human orfeome database v8.1
NFATC1	Human orfeome database v8.1
SOX2	Human orfeome database v8.1
c-JUN	Yvette Habraken Lab
ZNF148	Human orfeome database v8.1
IRF4	Human orfeome database v8.1
ZNF384	Human orfeome database v7.1
TEAD2	Human orfeome database v8.1
TEAD4	Human orfeome database v8.1
FLI1	Human orfeome database v7.1
KLF15	Human orfeome database v8.1
TCF20	PMID 35074918
ZNF609	PMID 28041881
GR-ΔNTD	Cloned from pDONOR-GR
GR-ΔLBD	Cloned from pDONOR-GR
NIPBL C1 ^{WT} domain	Cloned from pPB-3xFLAG-Halo-NIPBL-WT
NIPBL C2 ^{WT} domain	Cloned from pPB-3xFLAG-Halo-NIPBL-WT
NIPBL C2 ^{mut} domain	Cloned from pPB-3xFLAG-Halo-NIPBL-C2 ^{mut}

Table S2: Forward and reverse primers for the cloning of gPCA ORFs

	PRIMER FWD AttB1	PRIMER REV AttB2
NIPBL C1 ^{WT} domain	GGGGACAACTTGTACAAAAAAA GTTGGCATGCCCGGAATCGCT TCTCTGAC	GGGGACAACTTGTACAAGAAAGT TGCATGCCGCTCTGCACGTATC
NIPBL C2 ^{WT} domain	GGGGACAACTTGTACAAAAAAA GTTGGCATGTACATCCAGATGG TTACAGCTCTGG	GGGGACAACTTGTACAAGAAAGT TGCTCTCCAGGACTCTCAGGATC
NIPBL C2 ^{mut} domain	GGGGACAACTTGTACAAAAAAA GTTGGCATGTACATCCAGATGG TTACAGCTCTGG	GGGGACAACTTGTACAAGAAAGT TGCTCTCCAGGACTCTCAGGATC
GR- ΔNTD	GGGGACAACTTGTACAAAAAAA GTTGGCATGAGACCAGATGTG AGTTCTCCTCC	GGGGACAACTTGTACAAGAAAGT TGTTTCTGATGAAACAGAAGCTTT TGATATTCCATTG
GR- ΔLBD	GGGGACAACTTGTACAAAAAAA GTTGGCATGGACTCCAAGAAC CCTTAGCTCCCC	GGGGACAACTTGTACAAGAAAGT TGGTCTGTGAGACTCCTGCAGTG
NIPBL	GGGGACAACTTGTACAAAAAAA GTTGGCATGAACGGCGACATG CCTCACGTGC	GGGGACAACTTGTACAAGAAAGT TGAAGAGCTTGCGCCCTTAGC AGCG
MAU2	GGGGACAACTTGTACAAAAAAA GTTGGCATGGCGCACAGGCG GCGG	GGGGACAACTTGTACAAGAAAGT TGCAGAAGGCTGGCCAGGCTGG
SMC1A	GGGGACAACTTGTACAAAAAAA GTTGGCATGGGTTCTGAAA CTGATTGAG	GGGGACAACTTGTACAAGAAAGT TGCTGCTCATTGGGTTGGGG
SMC3	GGGGACAACTTGTACAAAAAAA GTTGGCATGTACATCAAGCAG GTGATCATCCAG	GGGGACAACTTGTACAAGAAAGT TGACCATGCGTGGATCGTCTTC
RAD21	GGGGACAACTTGTACAAAAAAA GTTGGCATTTCTACGCACATT TTGTCTCAG	GGGGACAACTTGTACAAGAAAGT TGGATAATATGGAACCGTGGTCCA GGG
PDS5B	GGGGACAACTTGTACAAAAAAA GTTGGCATGGCTCATTCAAAGA CAAGGACC	GGGGACAACTTGTACAAGAAAGT TGTCGTCTCTCGTTGGAGCTTC
CTCF	GGGGACAACTTGTACAAAAAAA GTTGGCATGGAAGGTGAGGCG GTTG	GGGGACAACTTGTACAAGAAAGT TGCCGGTCCATCATGCTGAGG
AR	GGGGACAACTTGTACAAAAAAA GTTGGCATGGAAGTGCAGTTA GGGCTGGG	GGGGACAACTTGTACAAGAAAGT TGCTGGGTGTGGAAATAGATGGGC
THR8	GGGGACAACTTGTACAAAAAAA GTTGGCATGGCGATGCCATG ACTCCC	GGGGACAACTTGTACAAGAAAGT TGAACATCCTCGAACACTCCAAGA AC

GR	GGGGACAACTTGTACAAAAAA GTTGGCATGGACTCCAAAGAAT CCTTAGCTCCC	GGGGACAACTTGTACAAGAAAGT TGTTTCTGATGAAACAGAAGCTTT TGATATTCC
PPAR α	GGGGACAACTTGTACAAAAAA GTTGGCATGGTGGACACGGAA AGCCCCAC	GGGGACAACTTGTACAAGAAAGT TGAACGTACATGTCCCTGTAGATCT CC
RXR	GGGGACAACTTGTACAAAAAA GTTGGCATGGACACCAAACATT TCCTGCCG	GGGGACAACTTGTACAAGAAAGT TGAACAGTCATTGGTGC CGGC
TCF20	GGGGACAACTTGTACAAAAAA GTTGGCATGCAGTCCTTCGG GAGCAAAGC	GGGGACAACTTGTACAAGAAAGT TGTCTCCACAGTCTCACCTTGCT TAG
ZNF609	GGGGACAACTTGTACAAAAAA GTTGGCATGTCCTTGAGCAGT GGAGCCTG	GGGGACAACTTGTACAAGAAAGT TGCCTCCGGGGGGGTGG

Video S1: Representative fast SMT movies for NIPBL-WT and mutants

Montage of representative SMT movies collected with the fast SMT protocol (exposure time = 12 ms, interval = 12 ms). Left to right: mNIPBL-WT, C1^{mut}, C2^{mut}, and C1+C2^{mut}. Trajectories longer than 7 frames are shown in red. Scale bar = 2 μ m and playback speed in 125 frames/s.

Related to Figure 1.

Video S2: Representative intermediate SMT movies for NIPBL-WT and mutants

Montage of representative SMT movies collected with the intermediate SMT protocol (exposure time = 10 ms, interval = 200 ms). Left to right: mNIPBL-WT, C1^{mut}, C2^{mut}, and C1+C2^{mut}. Trajectories longer than 7 frames are shown in red. Scale bar = 2 μ m and playback speed in 50 frames/s.

Related to Figure 1.